Pigmentary disorders induced by anticancer agents. Part II: Targeted therapies;Anomalies pigmentaires induites par les traitements anticancéreux. Deuxième partie : Les thérapies ciblées

Annales de Dermatologie et de Venereologie

Volumn 140, Issue 4, 2013, Pages 266-273

  Sibaud, V ^a   Robert, C ^b  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

CTLA4 inhibitors; Multikinase inhibitors; PD1; Pigmentary disorders; RAF inhibitors; Targeted anticancer therapies

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IMATINIB; PAZOPANIB; PROGRAMMED DEATH 1 LIGAND 1; RAF INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB;

BLUE NEVUS; DRUG ERUPTION; HAIR; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; MUCOSA; NAIL; NEVUS; PIGMENT DISORDER; REVIEW; SKIN; VITILIGO;

EID: 84876576654     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2013.01.442     Document Type: Review

References (76)

1. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
2. Sibaud V, Fricain JC, Baran R, Robert C. Anomalies pigmentaires induites par les traitements anticancéreux. Première partie: chimiothérapies. Ann Dermatol Venereol 2013;140:183-96.
3. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16: 1425-33.
4. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007;56:317-26.
5. Agero ALC, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55:657-70.
6. Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011;19:1079-95.
7. Belloni B, Schonewolf N, Rozati S, Goldinger SM, Dummer R. Cutaneous drug eruptions associated with the use of new oncological drugs. Chem Immunol Allergy 2012;97: 191-202.
8. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Rev Cancer 2006;6:803-12.
9. Jatoi A, Thrower A, Sloan JA, Flynn PJ, Wentworth-Hartung NL, Dakhil SR, et al. Does sunscreen prevent growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North central Cancer Treatment Group (NC05C4). Oncologist 2010;15:1016-22.
10. Thatcher N, Nicolson M, Groves RW, Steele J, Eaby B, Dunlop J, et al. Expert consensus on the management of erlotinib-associated cutaneous toxicity in the UK. Oncologist 2009;14:840-7.
11. Luu M, Boone SL, Patel J, Sullivan P, Rademaker AW, Balagula Y, et al. Higher severity of erlotinib-induced rash is associated with lower skin phototype. Clin Exp Dermatol 2011;36:733-8.
12. Sibaud V, Delord JP, Chevreau C, Gangloff D, Garrido-Stowhas I. Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology. Ann Chir Plast Esthet 2012;57:106-13.
13. Sibaud V, Garrido-Stowhas I, Cottura E, Chevreau C. Dermatologic side effects induced by new angiogenesis inhibitors. Bull Cancer 2011;98:1221-9.
14. Grichnik JM, Burch JA, Shea CR. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998;111:233-8.
15. Tsao AS, Kantarjian H, Cortes J, O Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003;98:2483-7.
16. Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V. Pigmentary changes in chronic myeloid leukaemia patients treated with imatinib mesylate. Ann Oncol 2004;15:358-9.
17. Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther 2011;24:386-95.
18. Valeyrie-Allanore L. Cutaneous manifestations of BCR-ABL, c-KIT et PDGFR inhibitors. In: Sibaud V, Robert C, editors. Cutaneous side effects induced by targeted anticancer therapies: a new dermatology. Toulouse: Privat; 2010. p. 41-59.
19. Brazzelli V, Prestinari F, Barbagallo T, Rona C, Orlandi E, Passamonti F, et al. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. J Eur Acad Dermatol 2006;21:384-7.
20. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukamias: a prospective study of 54 patients. J Am Acad Dermatol 2003;48:201-6.
21. Alexandrescu DT, Dasanu CA, Farzanmehr H, Kauffman CL. Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J 2008;14:7.
22. Campbell T, Felsten L, Moore J. Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome. Arch Dermatol 2009;145: 1313-6.
23. Mariani S, Abruzzese E, Basciani S, Fiore D. Reversible hair depigmentation in a patient treated with imatinib. Leukemia Res 2010;35:e65-6.
24. Balagula Y, Pulitzer MP, Maki RG, Myskowski PL. Pigmentary changes in a patient treated with imatinib. J Drugs Dermatol 2011;10:1062-6.
25. Cario-Andre M, Ardilouze L, Pain C, Gauthier Y, Mahon FX, Taieb A. Imatinib mesylate inhibits melanogenesis in vitro. Br J Dermatol 2006;155:493-4.
26. Etienne G, Cony-Makhoul P, Mahon FX. Imatinib mesylate and grey hair. N Engl J Med 2002;347:446.
27. Han H, Yu YY, Wang YH. Imatinib mesylate-induced repigmentation of vitiligo lesions in a patient with recurrent gastrointestinal stromal tumors. J Am Acad Dermatol 2008;59:s80-3.
28. Sun A, Akin RS, Cobos E, Smith J. Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor. J Drugs Dermatol 2009;8:395-8.
29. Robert C, Sibaud V, Mateus C, Cherpelis BS. Advances in the management of cutaneous toxicities of targeted therapies. Semin Oncol 2012;39:227-40.
30. Li CC, Malik SM, Blaeser BF, Dehni WJ, Kabani SP, Boyle N, et al. Mucosal pigmentation caused by imatinib: report of three cases. Head Neck Pathol 2012;6:290-5.
31. Resende RG, Teixeira RG, Vasconcelos FD, Silva ME, Abreu MH, Gomez RS. Imatinib-associated hyperpigmentation of the palate in post-HSCT patient. J Craniomaxillofac Surg 2012;40:e140-5.
32. Mattsson U, Halbritter S, MörnerSerikoff E, Christerson L, Warfvinge G. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111:e12-6.
33. Lewis DM. Diffuse pigmentation of the palate. J Okla Dent Assoc 2009;100:24-5.
34. Mcpherson T, Sherman V, Turner R. Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol 2009;23:82-3.
35. Sibaud V, Chevreau C. Dermatologic manifestations of angiogenesis inhibitors. In: Sibaud V, Robert C, editors. Cutaneous side effects induced by targeted anticancer therapies: a new dermatology. Toulouse: Privat; 2010. p. 41-59.
36. Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008;16:557-66.
37. Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009;161:1045-51.
38. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356: 115-24.
39. Robert C, Spatz A, Faivre S, Armand JP, Raymond E. Tyrosine kinase inhibition and grey hair. Lancet 2003;361:1056.
40. Hartmann JT, Kanz L. Sunitinib and periodic hair depigmentation due to temporary c-kit inhibition. Arch Dermatol 2008;144:1525-6.
41. Al Enazi MM, Kadry R, Mitwali H. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma. J Am Acad Dermatol 2009;61:905-6.
42. Keisner SV, Shah SR. Pazopanib-the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011;71:443-54.
43. Balagula Y, Wu S, Su X, Feldman DR, Lacouture ME. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2012;30:1773-81.
44. Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle B, Gibson DM, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15:4220-7.
45. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8.
46. Yang CH, Chuang CK, Hsieh JJ, Chang JWC. Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma. Expert Opin Drug Saf 2010;9:459-70.
47. Yau T, Chen PJ, Chan P, Curtis CM, Murphy PS, Suttle AB. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res 2011;17:1-10.
48. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11:962-72.
49. Sideras K, Menefee ME, Burton JK, Erlichman C, Bible KC. Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib. J Clin Oncol 2010;28:e312-3.
50. Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol 2008;144:820-2.
51. Bennani-Lahlou M, Mateus C, Escudier B, Massard C, Soria JC, Spatz A, et al. Eruptive naevus associated with sorafenib treatment. Ann Dermatol Venereol 2008;135:672-4.
52. Anforth R, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, et al. Manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012;167:1153-60.
53. Haenssle HA, Kraus SL, Brehmer F, Kretschmer L, Völker B, Asper H, et al. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch Dermatol 2012:1-3, http://dx.doi.org/10.1001/archdermatol.2012.2649. Epub ahead of print.
54. Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 2012;67:1265-72.
55. Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012;30:2375-83.
56. Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl Med 2011;365:1448-50.
57. Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009;14:378-90.
58. Wells Jr SA, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-72.
59. Kong HH, Fine HA, Stern JB, Turner MLC. Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol 2009;145:923-5.
60. Robert C. Vandetanib (Zactima®). In: Sibaud V, Robert C, editors. Cutaneous side effects induced by targeted anticancer therapies: a new dermatology. Toulouse: Privat; 2010. p. 41-59.
61. Natale RB, Thongprasert F, Greco A, Thomas M, Tsai CM, Sumpaweravong P, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29: 1059-66.
62. Chang CH, Chang JWC, Hui CY, Yang CH. Severe photosensitivity reaction to vandetanib. J Clin Oncol 2009;27:e114-5.
63. Leboulleux S, Bastholt L, Krause T, De la Fouchardiere C, Tennvall J, Awada A, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13:897-905.
64. Son YM, Roh JY, Cho EK, Lee Jr. Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel. Ann Dermatol 2011;23:s314-8.
65. Brooks S, Linehan WM, Srinivasan R, Kong HH. Successful laser treatment of vandetanib-associated cutaneous pigmentation. Arch Dermatol 2011;147:364-5.
66. Rappersberger K, Honigsmann H, Ortel B, Tanew A, Konrad K, Wolff K. Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery. J Invest Dermatol 1989;93:201-9.
67. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
68. Robert C, Thomas L, Bondakero I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
69. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-8.
70. Robert C, Ghiringhelli F. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockage in patients with metastatic melanoma? Oncologist 2009;14:848-61.
71. Trinh VA, Hwu WJ. Ipilimumab in the treatment of melanoma. Expert Opin Biol Ther 2012;12:773-82.
72. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010;37:499-507.
73. Weber JS, Kahler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-7.
74. Robert C. Manifestations dermatologiques des anticorps anti-CTLA-4. In: Sibaud V, Robert C, editors. Manifestations cutanées des thérapies ciblées anticancéreuses : une Nouvelle Dermatologie. Toulouse: Privat; 2010. p. 89-94.
75. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
76. Brahmer JR, tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.